Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Cancer Invest. 2017 Jan 2;35(1):32-35. doi: 10.1080/07357907.2016.1253710. Epub 2016 Dec 2.

Abstract

The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who underwent pre-treatment biopsy for RNA biomarker analysis, 25 were treated with dasatinib 70 mg twice daily. There were no responses. Five patients discontinued treatment due to toxicity. Three patients had minor biopsy-related pneumothoraces. Given the lack of responses, no biomarkers were analyzed. Dasatinib 70 mg twice daily does not have activity nor is it well tolerated in unselected patients with advanced stage, previously treated NSCLC.

Keywords: Non-small cell lung cancer; Src; gene expression.

Publication types

  • Clinical Trial, Phase II

MeSH terms

  • Administration, Oral
  • Aged
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Dasatinib / administration & dosage*
  • Dasatinib / adverse effects
  • Dasatinib / therapeutic use
  • Drug Administration Schedule
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors / administration & dosage*
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use
  • Treatment Failure
  • Treatment Outcome
  • src-Family Kinases / antagonists & inhibitors

Substances

  • Protein Kinase Inhibitors
  • src-Family Kinases
  • Dasatinib